News
AAD: J&J’s oral IL-23 drug shows durability in psoriasis
Patients with plaque psoriasis treated with Johnson & Johnson’s oral IL-23 inhibitor JNJ-2113 have been shown to maintain skin clearance for up to a year, pointing to
